Gefurulimab Improved Myasthenia Gravis Outcomes in 2026
The experimental once-weekly injection significantly boosted muscle strength and daily function in clinical trial participants.
Updated on Oct. 14, 2026 in Stroke
Live Poll
Should regulatory authorities prioritize the approval of at-home administration for new rare disease treatments?
In 2026, the international PREVAIL phase 3 clinical trial demonstrated that the experimental drug gefurulimab successfully improves daily function and muscle strength for patients with chronic myasthenia gravis. The treatment, administered as a subcutaneous injection, outperformed placebos across key performance metrics throughout the six-month study period.
Why it matters
Myasthenia gravis is a chronic autoimmune disease that currently lacks a cure, making the development of effective, patient-administered therapies essential. International collaboration enabled the trial to gather robust data despite the rarity of the condition.
In the trial of 260 patients across 20 countries, 65.5% of those treated with gefurulimab reached the daily activity improvement criterion compared to 52.2% in the placebo group. Long-term safety and efficacy outcomes are currently being evaluated.
The players
Bellvitge Universitary Hospital
This facility is a major medical center in Spain that coordinated the national participation in the international PREVAIL trial.
The details
Gefurulimab allows for home-based care through a once-weekly subcutaneous injection administered by patients or their caregivers. Researchers utilized a multinational collaboration of 113 centers to ensure the study population was large enough to generate statistically significant results for this rare autoimmune disorder.
Timeline
Improvements in daily activities were observed during the first week of treatment.
Clinical improvements in muscle strength became evident from the fourth week onward.
The primary study period concluded at 6 months to measure final improvement criteria.
Health Landscape
This study represents a significant advancement in clinical trial methodology by successfully utilizing a multinational model to study rare diseases. It serves as a precedent for future research into chronic autoimmune conditions that historically struggle with low enrollment numbers.
Patients may eventually gain access to a manageable home-based treatment that addresses the daily functional limitations caused by myasthenia gravis. The once-weekly injection schedule is designed to improve lifestyle autonomy compared to clinical-based treatment options.
The takeaway
The successful trial of gefurulimab offers a promising new direction for managing rare autoimmune diseases through subcutaneous, patient-led administration. This outcome highlights the effectiveness of international data pooling when addressing medical conditions with limited patient populations.
Further reading
Learn more about the latest developments in neuro-immunology and research in the Stroke section.
More information
Access the full findings in the JAMA Neurology study report.
Source note: This article includes information reported by Biotech-spain.
Live Poll
Should regulatory authorities prioritize the approval of at-home administration for new rare disease treatments?
